P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406)

BACKGROUND: Depatux-M is a n antibody-drug-conjugate consisting of an antibody (ABT-806) specific to the activated conformation of epidermal growth factor receptor (EGFR) bound to the toxin monomethylauristatin-F. In the primary analysis on EORTC 1410 we reported a trend (p = 0.06) towards improved...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: van den Bent, M, French, P, Eoli, M, Sepulvado, J, Walenkamp, A, Weller, M, Looman, J, Ansell, P, Gorlia, T, Golfinopoulos, V
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2018
Ämnen:
Poster Presentations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144235/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.094
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk